CNS Pharmaceuticals Files S-1 for Public Offering

TL;DR

CNS Pharma filed an S-1, looks like they're raising cash soon.

AI Summary

CNS Pharmaceuticals, Inc. filed an S-1 registration statement on July 12, 2024, indicating plans to offer securities. The company, incorporated in Nevada with principal offices in Houston, Texas, operates in the pharmaceutical preparations sector. This filing is a standard step for companies intending to raise capital through public offerings.

Why It Matters

This S-1 filing signals CNS Pharmaceuticals' intent to access public markets for capital, which could fund its drug development and commercialization efforts.

Risk Assessment

Risk Level: medium — S-1 filings indicate a company is seeking to raise capital, which can be a positive sign but also carries inherent risks associated with public offerings and the company's specific stage of development.

Key Numbers

• 333-280790 — SEC File Number (Identifies this specific registration statement)

Key Players & Entities

• CNS Pharmaceuticals, Inc. (company) — Registrant
• July 12, 2024 (date) — Filing date
• Nevada (jurisdiction) — State of incorporation
• Houston, Texas (location) — Principal executive offices
• John Climaco (person) — Chief Executive Officer
• Cavas S. Pavri (person) — Copies to counsel
• Johnathan C. Duncan (person) — Copies to counsel
• ArentFox Schiff LLP (company) — Counsel

FAQ

Key Financial Figures

• $4.4 million — eds to us of a maximum of approximately $4.4 million; however, we cannot predict when and in
• $1.26 — ported on the NASDAQ Capital Market was $1.26 per share. There is no established publ
• $750,000 — eed to pay HPI: (i) development fees of $750,000 over a three-year period beginning Nove
• $50,000 — (ii) a 2% royalty on net sales; (iii) a $50,000 per year license fee; (iv) milestone pa
• $100,000 — license fee; (iv) milestone payments of $100,000 upon the commencement of a Phase II tri
• $1.0 million — he commencement of a Phase II trial and $1.0 million upon the approval of a New Drug Applica
• $1,134,000 — he Company agreed to fund approximately $1,134,000 over a two-year period. The Company pai
• $334,000 — r period. The Company paid and recorded $334,000 in 2020 related to this agreement in re
• $800,000 — statements of operations. The remaining $800,000 was paid in 2021. The principal investi
• $0.001 — par value per share, which will remain $0.001. Unless the context expressly dictates
• $3.75 — ccompanying Series C Common Warrant was $3.75. The closing of the June 14 Offering an
• $3.62 — y exercisable, has an exercise price of $3.62 per share, and will expire five years f
• $80,000 — also agreed to reimburse AGP for up to $80,000 in legal fees and expenses. 4 June 2
• $2.45 — ccompanying Series D Common Warrant was $2.45. The closing of the June 26 Offering an
• $2.32 — y exercisable, has an exercise price of $2.32 per share, and will expire five years f

Filing Documents

• cns_s1.htm (S-1) — 240KB
• cns_ex0501.htm (EX-5.1) — 7KB
• cns_ex2301.htm (EX-23.1) — 3KB
• cns_ex107.htm (EX-FILING FEES) — 12KB
• image_001.jpg (GRAPHIC) — 7KB
• image_002.jpg (GRAPHIC) — 3KB
• 0001683168-24-004799.txt ( ) — 278KB

RISK FACTORS

RISK FACTORS 8 INCORPORATION BY REFERENCE 8 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 9

USE OF PROCEEDS

USE OF PROCEEDS 10 DIVIDEND POLICY 10 SELLING SHAREHOLDERS 10 PLAN OF DISTRIBUTION 12

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 14 LEGAL MATTERS 18 EXPERTS 18 WHERE YOU CAN FIND MORE INFORMATION 18 ABOUT THIS PROSPECTUS This prospectus relates to the resale by the selling shareholders identified in this prospectus under the caption “Selling Shareholders,” from time to time, of up to an aggregate of 2,359,000 shares of our common stock issuable upon exercise of certain outstanding common stock purchase warrants. We are not selling any shares of our common stock under this prospectus, and we will not receive any proceeds from the sale of shares of common stock offered hereby by the selling shareholders, although we will receive cash from the exercise of the outstanding common stock purchase warrants. You should read this prospectus, any documents that we incorporate by reference in this prospectus and the information below under the caption “Where You Can Find More Information” and “Incorporation By Reference” before making an investment decision. You should rely only on the information contained in or incorporated by reference into this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference herein. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized information or representation. You should assume that the information in this prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of a security. The distribution of this prospectus and the issuance of the securities in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospec